Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Artiva Biotherapeutics (ARTV) Income from Continuing Operations (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Income from Continuing Operations for 3 consecutive years, with 20770000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Income from Continuing Operations fell 29.09% to 20770000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was 83851000.0, a 35.39% decrease, with the full-year FY2025 number at 83851000.0, down 28.27% from a year prior.
  • Income from Continuing Operations was 20770000.0 for Q4 2025 at Artiva Biotherapeutics, up from 21525000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 11386000.0 in Q4 2023 to a low of 21525000.0 in Q3 2025.
  • A 3-year average of 16899600.0 and a median of 16289500.0 in 2024 define the central range for Income from Continuing Operations.
  • Biggest YoY gain for Income from Continuing Operations was 29.09% in 2025; the steepest drop was 46.71% in 2025.
  • Artiva Biotherapeutics' Income from Continuing Operations stood at 11386000.0 in 2023, then crashed by 41.31% to 16090000.0 in 2024, then fell by 29.09% to 20770000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Income from Continuing Operations are 20770000.0 (Q4 2025), 21525000.0 (Q3 2025), and 21249000.0 (Q2 2025).